Epilepsy is primarily treated symptomatically—that is, the majority of the available medications aim to suppress seizures ...

Epilepsy is primarily treated symptomatically - that is, the majority of the available medications aim to suppress seizures ...

Furthermore, we demonstrated that the learned compensatory mechanism contributing to associative morphine tolerance requires an action of CCK at the CCK-B receptor in the L/BL amygdala.

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

The patents surrounding Soliris (eculizumab) extend its period of market exclusivity from 2022 to 2027, but Alexion thinks it has found a chink in the legal armour. Soliris is still the mainstay ...

The approval positions Amgen’s Bkemv (formerly ABBP 959) as a key competitor to complement C5 inhibitor Soliris (eculizumab), which contributed $3.1 billion in global revenues to AZ last year.